Literature DB >> 12073144

A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule.

Marc Jacobsen1, Steve Hoffmann, Sabine Cepok, Susanne Stei, Andreas Ziegler, Norbert Sommer, Bernhard Hemmer.   

Abstract

CD45, encoded by the protein tyrosine phosphatase receptor type C ( PTPRC) gene, is essentially involved in maturation, activation, and migration of immune cells. Lack of CD45 results in severe immunodeficiency, and alterations of the receptor may result in autoimmunity. Here, we describe a novel mutation in PTPRCas a cause of variant CD45 expression in humans. Several members of a multiple sclerosis multiplex family showed expression of CD45RA on memory T cells and monocytes. The variant expression pattern was linked to the PTPRCgene by DNA microsatellite studies. DNA analysis identified a novel point mutation in exon 4 (position 59 C-->A) in all family members with variant CD45 expression, but not in donors with normal CD45 expression. The mutation interferes with alternative splicing and alters amino acid sequence (H-->Q), interfering with antibody binding to the CD45RA domain. Overall, we describe the first mutation in PTPRCthat interferes with splicing and results in surface expression of a structurally altered CD45 molecule in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12073144     DOI: 10.1007/s00251-002-0455-7

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  15 in total

Review 1.  New approaches to investigating heterogeneity in complex traits.

Authors:  R Bomprezzi; P E Kovanen; R Martin
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

2.  Alternative splicing networks regulated by signaling in human T cells.

Authors:  Nicole M Martinez; Qun Pan; Brian S Cole; Christopher A Yarosh; Grace A Babcock; Florian Heyd; William Zhu; Sandya Ajith; Benjamin J Blencowe; Kristen W Lynch
Journal:  RNA       Date:  2012-03-27       Impact factor: 4.942

Review 3.  CD45: all is not yet crystal clear.

Authors:  Nick Holmes
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

Review 4.  Environmental influences on RNA processing: Biochemical, molecular and genetic regulators of cellular response.

Authors:  Athma A Pai; Francesca Luca
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-09-14       Impact factor: 9.957

5.  Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing.

Authors:  Florian Heyd; Kristen W Lynch
Journal:  Mol Cell       Date:  2010-10-08       Impact factor: 17.970

6.  A high-frequency polymorphism in exon 6 of the CD45 tyrosine phosphatase gene (PTPRC) resulting in altered isoform expression.

Authors:  Tara Stanton; Sally Boxall; Kouzo Hirai; Ritu Dawes; Susan Tonks; Tomoyo Yasui; Yasushi Kanaoka; Nadira Yuldasheva; Osamu Ishiko; Walter Bodmer; Peter C L Beverley; Elma Z Tchilian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

Review 7.  CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans.

Authors:  Tara Stanton; Sally Boxall; Andrea Bennett; Pontiano Kaleebu; Christine Watera; Jimmy Whitworth; Neil French; Ritu Dawes; Adrian V S Hill; Walter Bodmer; Peter C L Beverley; Elma Z Tchilian
Journal:  Immunogenetics       Date:  2004-04-01       Impact factor: 2.846

Review 8.  Protein tyrosine phosphatases as potential therapeutic targets.

Authors:  Rong-Jun He; Zhi-Hong Yu; Ruo-Yu Zhang; Zhong-Yin Zhang
Journal:  Acta Pharmacol Sin       Date:  2014-09-15       Impact factor: 6.150

Review 9.  Genomics of alternative splicing: evolution, development and pathophysiology.

Authors:  Eric R Gamazon; Barbara E Stranger
Journal:  Hum Genet       Date:  2014-01-01       Impact factor: 4.132

10.  Cytokine-induced dicing and splicing in the beta-cell and the immune response in type 1 diabetes.

Authors:  John C Hutton; Howard W Davidson
Journal:  Diabetes       Date:  2010-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.